Related Experiment Video
Updated: Aug 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Treatment strategy to obtain cure for recurrent advanced breast cancer]
1Aichi Cancer Center, Tokai University School of Medicine.
Abstract:
The three-year survival rate of a total of 186 patients with recurrent advanced breast cancer was 86% for complete responders, 27% for partial responders, and 29% for patients remaining in stable diseases, respectively, at our two institutions. Thus, the results indicated that a complete response is the first step for long-term survival. High-dose chemotherapy with autologous stem cell support was administered after 4 cycles of induction chemotherapy. The results showed 12 complete response (60%) out of 20 patients, and 5 cases survived with no evidences of disease for 5-31 months. Both taxol and taxotere achieved response rates exceeding 50% in phase II trials on advanced breast cancer and therefore were expected to have a role in combination regimens with other drugs.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Tumor Immunotherapy

